Oesophageal squamous cell carcinoma (ESCC) patients whose tumours have EGFR CNG and/or EGFR protein overexpression may represent a subgroup that benefits from EGFR inhibitor monotherapy [7, 12, 13]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.